Cargando…

Oral fosfomycin activity against Klebsiella pneumoniae in a dynamic bladder infection in vitro model

INTRODUCTION: The use of oral fosfomycin for urinary tract infections (UTIs) caused by non-Escherichia coli uropathogens is uncertain, including Klebsiella pneumoniae, the second most common uropathogen. METHODS: A multicompartment bladder infection in vitro model was used with standard media and sy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Abbott, Iain J., van Gorp, Elke, Wyres, Kelly L., Wallis, Steven C., Roberts, Jason A., Meletiadis, Joseph, Peleg, Anton Y.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9047678/ https://www.ncbi.nlm.nih.gov/pubmed/35211736 http://dx.doi.org/10.1093/jac/dkac045

Ejemplares similares

Oral ciprofloxacin activity against ceftriaxone-resistant Escherichia coli in an in vitro bladder infection model
por: Abbott, Iain J, et al.
Publicado: (2022)

1386. Efficacy of Repeat Dosing of Oral Fosfomycin in a Dynamic Bladder Infection In Vitro Model
por: Abbott, Iain, et al.
Publicado: (2018)

Synergistic activity of fosfomycin–meropenem and fosfomycin–colistin against carbapenem resistant Klebsiella pneumoniae: an in vitro evidence
por: Bakthavatchalam, Yamuna Devi, et al.
Publicado: (2020)

In vitro antibacterial effect of fosfomycin combination therapy against colistin-resistant Klebsiella pneumoniae
por: Yu, Wei, et al.
Publicado: (2018)

Evaluation of the combination treatments with intravenous fosfomycin for carbapenem-resistant Klebsiella pneumoniae
por: Önal, Uğur, et al.
Publicado: (2023)

Coexistence of Fosfomycin and Colistin Resistance in Klebsiella pneumoniae: Whole-Genome Shotgun Sequencing
por: Veeraraghavan, Balaji, et al.
Publicado: (2016)

Synergistic Activity of Colistin/Fosfomycin Combination against Carbapenemase-Producing Klebsiella pneumoniae in an In Vitro Pharmacokinetic/Pharmacodynamic Model
por: Wang, Jin, et al.
Publicado: (2018)

In vitro Pharmacokinetics/Pharmacodynamics Evaluation of Fosfomycin Combined with Amikacin or Colistin against KPC2-Producing Klebsiella pneumoniae
por: Yu, Wei, et al.
Publicado: (2017)

Nitrofurantoin and Fosfomycin for Extended Spectrum Beta-lactamases Producing Escherichia coli and Klebsiella pneumoniae
por: Tulara, Neeraj Kumar
Publicado: (2018)

Transporter Genes and fosA Associated With Fosfomycin Resistance in Carbapenem-Resistant Klebsiella pneumoniae
por: Wang, Yu-Ping, et al.
Publicado: (2022)

The diversity of Klebsiella pneumoniae surface polysaccharides
por: Follador, Rainer, et al.
Publicado: (2016)

In Vitro Susceptibility of Multi-Drug Resistant Klebsiella pneumoniae Strains Causing Nosocomial Infections to Fosfomycin. A Comparison of Determination Methods
por: Mączyńska, Beata, et al.
Publicado: (2021)

In Vitro and In Vivo Synergism of Fosfomycin in Combination with Meropenem or Polymyxin B against KPC-2-Producing Klebsiella pneumoniae Clinical Isolates
por: Ribeiro, Aghata Cardoso da Silva, et al.
Publicado: (2023)

The Role of fosA in Challenges with Fosfomycin Susceptibility Testing of Multispecies Klebsiella pneumoniae Carbapenemase-Producing Clinical Isolates
por: Elliott, Zachary S., et al.
Publicado: (2019)

Efficacy of Fosfomycin and Its Combination With Aminoglycosides in an Experimental Sepsis Model by Carbapenemase-Producing Klebsiella pneumoniae Clinical Strains
por: Cebrero-Cangueiro, Tania, et al.
Publicado: (2021)

fosA3 overexpression with transporter mutations mediates high-level of fosfomycin resistance and silence of fosA3 in fosfomycin-susceptible Klebsiella pneumoniae producing carbapenemase clinical isolates
por: Singkham-in, Uthaibhorn, et al.
Publicado: (2020)

Comment on: MDR carbapenemase-producing Klebsiella pneumoniae of the hypervirulence-associated ST23 clone in Poland, 2009–19
por: Lam, Margaret M C, et al.
Publicado: (2023)

Evaluation of Activity and Emergence of Resistance of Polymyxin B and ZTI-01 (Fosfomycin for Injection) against KPC-Producing Klebsiella pneumoniae
por: Diep, John K., et al.
Publicado: (2018)

Pharmacodynamics of Aerosolized Fosfomycin and Amikacin against Resistant Clinical Isolates of Pseudomonas aeruginosa and Klebsiella pneumoniae in a Hollow-Fiber Infection Model: Experimental Basis for Combination Therapy
por: Sime, Fekade Bruck, et al.
Publicado: (2016)

Kaptive 2.0: updated capsule and lipopolysaccharide locus typing for the Klebsiella pneumoniae species complex
por: Lam, Margaret M. C., et al.
Publicado: (2022)

Identification of fosA10, a Novel Plasmid-Mediated Fosfomycin Resistance Gene of Klebsiella pneumoniae Origin, in Escherichia coli
por: Huang, Ying, et al.
Publicado: (2020)

Characterization of fosfomycin resistance and molecular epidemiology among carbapenem-resistant Klebsiella pneumoniae strains from two tertiary hospitals in China
por: Wang, Haichen, et al.
Publicado: (2021)

Assessment of In-Vitro Synergy of Fosfomycin with Meropenem, Amikacin and Tigecycline in Whole Genome Sequenced Extended and Pan Drug Resistant Klebsiella Pneumoniae: Exploring A Colistin Sparing Protocol
por: AL-Quraini, Manawr, et al.
Publicado: (2022)

Evaluation of Fosfomycin-Sulbactam Combination Therapy against Carbapenem-Resistant Acinetobacter baumannii Isolates in a Hollow-Fibre Infection Model
por: Mohd Sazlly Lim, Sazlyna, et al.
Publicado: (2022)

Comment on: CG258 Klebsiella pneumoniae isolates without β-lactam resistance at the onset of the carbapenem-resistant Enterobacteriaceae epidemic in New York City
por: Wyres, Kelly L, et al.
Publicado: (2019)

Tracking key virulence loci encoding aerobactin and salmochelin siderophore synthesis in Klebsiella pneumoniae
por: Lam, Margaret M. C., et al.
Publicado: (2018)

A genomic surveillance framework and genotyping tool for Klebsiella pneumoniae and its related species complex
por: Lam, Margaret M. C., et al.
Publicado: (2021)

652. Comparison of fosfomycin (FOF) activity and prevalence of subpopulations between Escherichia coli (EC) and Klebsiella pneumoniae (KP) during susceptibility testing
por: Anderson, Jadyn C, et al.
Publicado: (2020)

Synergistic antibacterial effects of colistin in combination with aminoglycoside, carbapenems, cephalosporins, fluoroquinolones, tetracyclines, fosfomycin, and piperacillin on multidrug resistant Klebsiella pneumoniae isolates
por: Ontong, Julalak C., et al.
Publicado: (2021)

Oral fosfomycin for the treatment of chronic bacterial prostatitis
por: Karaiskos, Ilias, et al.
Publicado: (2019)

1690. Oral Fosfomycin for the Treatment of Bacterial Prostatitis
por: Kamath, Meghan, et al.
Publicado: (2020)

Multidrug-resistant Klebsiella pneumoniae: a retrospective study in Manaus, Brazil
por: Nakamura-Silva, Rafael, et al.
Publicado: (2022)

ESBL plasmids in Klebsiella pneumoniae: diversity, transmission and contribution to infection burden in the hospital setting
por: Hawkey, Jane, et al.
Publicado: (2022)

Assessing the Emergence of Resistance in vitro and Invivo: Linezolid Combined with Fosfomycin Against Fosfomycin-Sensitive and Resistant Enterococcus
por: Li, Yaowen, et al.
Publicado: (2022)

Convergence of virulence and MDR in a single plasmid vector in MDR Klebsiella pneumoniae ST15
por: Lam, Margaret M C, et al.
Publicado: (2019)

Genomic dissection of Klebsiella pneumoniae infections in hospital patients reveals insights into an opportunistic pathogen
por: Gorrie, Claire L., et al.
Publicado: (2022)

Genomic epidemiology and temperature dependency of hypermucoviscous Klebsiella pneumoniae in Japan
por: Le, Mi Nguyen-Tra, et al.
Publicado: (2022)

Correction: Synergistic antibacterial effects of colistin in combination with aminoglycoside, carbapenems, cephalosporins, fluoroquinolones, tetracyclines, fosfomycin, and piperacillin on multidrug resistant Klebsiella pneumoniae isolates
Publicado: (2021)

Fosfomycin Disk Diffusion Testing among Klebsiella pneumoniae Results in Frequent Inner Colonies and Categorical Disagreement Based on Conflicting Breakpoint Organization Recommendations
por: Bixby, Morgan L., et al.
Publicado: (2023)

Oral and intravenous fosfomycin in complicated urinary tract infections
por: López-Montesinos, Inmaculada, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_59mitm5v6s2s0q7q96lir7npcb